Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer

Neoplasia (United States)

Volumn 15, Issue 6, 2013, Pages 609-619

  Yakubov, Bakhtiyor ^a   Chelladurai, Bhadrani ^a   Schmitt, Jordan ^a   Emerson, Robert ^a   Turchi, John J ^a,b   Matei, Daniela ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN P100; PROTEIN P52; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84878654712     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121878     Document Type: Article

References (44)

1. Pincus JH and Waelsch H (1968). The specificity of transglutaminase. II. Structural requirements of the amine substrate. Arch Biochem Biophys 126, 44-52.
2. Akimov SS and Belkin AM (2001). Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98, 1567-1576.
3. Chen S, Lin F, Iismaa S, Lee KN, Birckbichler PJ, and Graham RM (1996). α1-Adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity. J Biol Chem 271, 32385-32391.
4. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, and Graham RM (2001). Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276, 20673-20678.
5. Fesus L and Piacentini M (2002). Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27, 534-539.
6. Liu S, Cerione RA, and Clardy J (2002). Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci USA 99, 2743-2747.
7. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, and Mehta K (2006). Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 66, 8788-8795.
8. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, and Matei D (2007). Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67, 7194-7202.
9. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, and Mehta K (2006). Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66, 10525-10533.
10. Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, and Cerione RA (2004). Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 279, 41461-41467.
11. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, and Matei D (2008). Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29, 1893-1900.
12. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, and Matei D (2012). Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31, 2521-2534.
13. Verma A and Mehta K (2007). Transglutaminase-mediated activation of nuclear transcription factor-κB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7, 559-565.
14. Satpathy M, Shao M, Emerson R, Donner DB, and Matei D (2009). Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem 284, 15390-15399.
15. Verma A, Guha S, Wang H, Fok JY, Koul D, Abbruzzese J, and Mehta K (2008). Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 14, 1997-2005.
16. Mehta K, Fok J, Miller FR, Koul D, and Sahin AA (2004). Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10, 8068-8076.
17. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, and Matei D (2009). Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69, 9192-9201.
18. Kotsakis P and Griffin M (2007). Tissue transglutaminase in tumour progression: friend or foe? Amino Acids 33, 373-384.
19. Verderio EA, Telci D, Okoye A, Melino G, and Griffin M (2003). A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 278, 42604-42614.
20. Winer J, Jung CK, Shackel I, and Williams PM (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270, 41-49.
21. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, and Fishman DA (2004). Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 64, 7045-7049.
22. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, et al. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1, 1223-1232.
23. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, and Casey G (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719-723.
24. Antonyak MA, Jansen JM, Miller AM, Ly TK, Endo M, and Cerione RA (2006). Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA 103, 18609-18614.
25. Akimov SS, Krylov D, Fleischman LF, and Belkin AM (2000). Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148, 825-838.
26. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, and Mehta K (2010). Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5, e13390.
27. Barre B and Perkins ND (2010). The Skp2 promoter integrates signaling through the NF-κB, p53, and Akt/GSK3β pathways to regulate autophagy and apoptosis. Mol Cell 38, 524-538.
28. Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, Kerl H, Otte M, and Schaider H (2010). HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol 130, 1893-1903.
29. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, and Cheng C (2011). CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121, 1064-1074.
30. Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T, Nakamura S, Niwa S, Ikeda S, Koga H, et al. (2010). Tumor necrosis factor-α regulates transforming growth factor-β-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 285, 4060-4073.
31. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, et al. (2008). Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68, 5849-5858.
32. Zemskov EA, Mikhailenko I, Hsia RC, Zaritskaya L, and Belkin AM (2011). Unconventional secretion of tissue transglutaminase involves phospholipiddependent delivery into recycling endosomes. PLoS One 6, e19414.
33. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, and Griffin M (2006). Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13, 1442-1453.
34. Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, and Greenberg CS (1999). Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 13, 1787-1795.
35. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, and Xu Y (2007). Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26, 2894-2901.
36. Shaw TJ, Senterman MK, Dawson K, Crane CA, and Vanderhyden BC (2004). Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10, 1032-1042.
37. Fu X and Hoffman RM (1993). Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13, 283-286.
38. Falasca L, Iadevaia V, Ciccosanti F, Melino G, Serafino A, and Piacentini M (2005). Transglutaminase type II is a key element in the regulation of the antiinflammatory response elicited by apoptotic cell engulfment. J Immunol 174, 7330-7340.
39. Kumar A, Gao H, Xu J, Reuben J, Yu D, and Mehta K (2011). Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 6, e20701.
40. Razani B, Reichardt AD, and Cheng G (2011). Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol Rev 244, 44-54.
41. Li Q and Verma IM (2002). NF-κB regulation in the immune system. Nat Rev Immunol 2, 725-734.
42. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et al. (2011). Overexpression of Fn14 promotes androgen-independent prostate cancer progression throughMMP-9 and correlates with poor treatment outcome. Carcinogenesis 32, 1589-1596.
43. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, and Winkles JA (2011). Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 10, 1276-1288.
44. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, and Ottensmeier C (1993). Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 53, 3830-3838.